KT-621 clinical trials
KT-621 is named as an intervention in 4 current clinical trials in our USA, Germany, Poland, South Korea, UK, Spain, Italy, Belgium, Austria, Czechia, Canada, Japan and Australia registers. 3 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Kymera Therapeutics, Inc. The most-studied condition is Eosinophilic Asthma. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for KT-621
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of KT-621
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654 · Eosinophilic Asthma
|
Phase 2 | Recruiting | Kymera Therapeutics, Inc | UK, USA, Germany, Spain, Italy, Belgium, Poland, Austria, South Korea |
|
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
NCT07677059 · Asthma (Diagnosis)
|
Phase 2 | Recruiting | Kymera Therapeutics, Inc | USA, Germany, Poland |
|
A Study to Evaluate Different Oral Formulations of KT-621
NCT07823205 · Healthy Participants
|
Phase 1 | Recruiting | Kymera Therapeutics, Inc | USA |
|
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015 · Atopic Dermatitis
|
Phase 2 | Active, closed | Kymera Therapeutics, Inc | USA, Germany, Poland, Czechia, Canada, Japan, South Korea, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
KT-621 in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing KT-621. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00 · Immune System Diseases
|
Phase 2 | Authorised | Kymera Therapeutics Inc | Austria, Germany, Belgium + 5 more |
Conditions studied with KT-621
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Kymera Therapeutics, Inc | 4 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about KT-621 trials
How many clinical trials are testing KT-621?
4 current trials in our USA, Germany, Poland, South Korea, UK, Spain, Italy, Belgium, Austria, Czechia, Canada, Japan and Australia registers name KT-621 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are KT-621 trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 3 with sites in USA, 2 with sites in Germany, 2 with sites in Poland, 1 with sites in South Korea, 1 with sites in UK, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium and 1 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors KT-621 clinical trials?
The lead sponsor is Kymera Therapeutics, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how KT-621 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how KT-621 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists KT-621 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.